CD8A and neoplasm: The study demonstrated that while the CD8+ T‐cell response to the NY‐ESO‐1 peptide vaccine‐targeted multiple epitopes, only a small fraction of the induced CD8+ T cells recognised the naturally processed target on tumour cells.73